


A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of

Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research
VectorY Therapeutics, a biotechnology company based in Amsterdam, Netherlands, has
